Skip to main content
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Analysts’ Top Healthcare Picks: Q32 Bio (QTTB), UnitedHealth (UNH)

Tipranks - Tipranks - Wed Apr 22, 5:30AM CDT

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Q32 Bio (QTTB), UnitedHealth (UNH) and Enanta Pharmaceuticals (ENTA) with bullish sentiments.

Claim 30% Off TipRanks

Q32 Bio (QTTB)

In a report released today, Joseph Pantginis from H.C. Wainwright reiterated a Buy rating on Q32 Bio, with a price target of $13.00. The company’s shares closed last Monday at $6.65, close to its 52-week low of $1.70.

According to TipRanks.com, Pantginis is a 5-star analyst with an average return of 21.7% and a 57.7% success rate. Pantginis covers the Healthcare sector, focusing on stocks such as Adlai Nortye Ltd. Sponsored ADR, NewAmsterdam Pharma Company, and Cadrenal Therapeutics, Inc. ;'>

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Q32 Bio with a $14.33 average price target.

See today’s best-performing stocks on TipRanks >>

UnitedHealth (UNH)

Evercore ISI analyst Elizabeth Anderson CFA maintained a Buy rating on UnitedHealth today. The company’s shares closed last Monday at $323.48.

According to TipRanks.com, CFA is a 1-star analyst with an average return of -2.3% and a 49.0% success rate. CFA covers the Healthcare sector, focusing on stocks such as Hinge Health, Inc. Class A, Fortrea Holdings Inc., and Privia Health Group. ;'>

The word on The Street in general, suggests a Strong Buy analyst consensus rating for UnitedHealth with a $368.70 average price target, which is a 13.7% upside from current levels. In a report issued on April 7, Wells Fargo also maintained a Buy rating on the stock with a $370.00 price target.

Enanta Pharmaceuticals (ENTA)

H.C. Wainwright analyst Brandon Folkes reiterated a Buy rating on Enanta Pharmaceuticals today and set a price target of $20.00. The company’s shares closed last Monday at $13.78.

According to TipRanks.com, Folkes is a 3-star analyst with an average return of 2.1% and a 41.3% success rate. Folkes covers the Healthcare sector, focusing on stocks such as Sagimet Biosciences, Inc. Class A, Rani Therapeutics Holdings, and Connect Biopharma Holdings. ;'>

Currently, the analyst consensus on Enanta Pharmaceuticals is a Strong Buy with an average price target of $19.67.

Read More on QTTB:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).